



Axonics® to Participate in the Piper Sandler Healthcare Conference

November 18, 2022

IRVINE, Calif.--(BUSINESS WIRE)--Nov. 18, 2022-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022.

Axonics is scheduled to present at 11:00 a.m. Eastern Time. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations [website](#).

About Axonics

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2022 [Financial Times](#) ranking of the 500 fastest growing companies in the Americas and No. 4 on the 2022 [Deloitte](#) Technology Fast 500™ following its No. 1 ranking in 2021.

Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company's best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221118005032/en/): <https://www.businesswire.com/news/home/20221118005032/en/>

Axonics

Neil Bhalodkar
Investor Relations
949-336-5293
ir@axonics.com

Source: Axonics, Inc.